AR113835A1 - Análogos y pepticuerpos de glp-2 para la administración antes, durante o después de la cirugía - Google Patents
Análogos y pepticuerpos de glp-2 para la administración antes, durante o después de la cirugíaInfo
- Publication number
- AR113835A1 AR113835A1 ARP180103232A ARP180103232A AR113835A1 AR 113835 A1 AR113835 A1 AR 113835A1 AR P180103232 A ARP180103232 A AR P180103232A AR P180103232 A ARP180103232 A AR P180103232A AR 113835 A1 AR113835 A1 AR 113835A1
- Authority
- AR
- Argentina
- Prior art keywords
- glp
- small intestine
- during
- peptibodies
- analogues
- Prior art date
Links
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 5
- 238000001356 surgical procedure Methods 0.000 title abstract 3
- 229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 title 1
- 210000000813 small intestine Anatomy 0.000 abstract 4
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 235000016236 parenteral nutrition Nutrition 0.000 abstract 2
- 238000002271 resection Methods 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 abstract 1
- 206010049416 Short-bowel syndrome Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 201000009019 intestinal benign neoplasm Diseases 0.000 abstract 1
- 235000015816 nutrient absorption Nutrition 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- CILIXQOJUNDIDU-ASQIGDHWSA-N teduglutide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 CILIXQOJUNDIDU-ASQIGDHWSA-N 0.000 abstract 1
- 229960002444 teduglutide Drugs 0.000 abstract 1
- 108010073046 teduglutide Proteins 0.000 abstract 1
- -1 teduglutide Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582055P | 2017-11-06 | 2017-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113835A1 true AR113835A1 (es) | 2020-06-17 |
Family
ID=66332372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103232A AR113835A1 (es) | 2017-11-06 | 2018-11-06 | Análogos y pepticuerpos de glp-2 para la administración antes, durante o después de la cirugía |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11660328B2 (enExample) |
| EP (1) | EP3706774A4 (enExample) |
| JP (2) | JP7296958B2 (enExample) |
| KR (1) | KR102825098B1 (enExample) |
| CN (1) | CN111629745A (enExample) |
| AR (1) | AR113835A1 (enExample) |
| AU (1) | AU2018360744A1 (enExample) |
| BR (1) | BR112020008936A2 (enExample) |
| CA (1) | CA3079523A1 (enExample) |
| IL (1) | IL274098B2 (enExample) |
| MX (1) | MX2020004620A (enExample) |
| TW (1) | TW201922279A (enExample) |
| WO (1) | WO2019090209A1 (enExample) |
| ZA (1) | ZA202002080B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7249492B2 (ja) * | 2017-08-22 | 2023-03-31 | タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド | Ｇｌｐ－２融合ポリペプチドならびに消化管の状態を処置および予防するための使用 |
| US20210355187A1 (en) * | 2018-10-24 | 2021-11-18 | Shire-Nps Pharmaceuticals, Inc. | Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| US20230129788A1 (en) * | 2020-03-30 | 2023-04-27 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| WO2021263040A1 (en) * | 2020-06-26 | 2021-12-30 | Shire-Nps Pharmaceuticals, Inc. | Stable peptibody formulations |
| CN115636876A (zh) * | 2021-07-20 | 2023-01-24 | 重庆派金生物科技有限公司 | 胰高血糖素样肽-2突变体的定向化学偶联物及其应用 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2025181330A1 (en) * | 2024-02-29 | 2025-09-04 | Vectivbio Ag | Dosage regimens for glucagon-like peptide 2 (glp-2) analogs |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1809318B1 (en) * | 2004-11-01 | 2013-06-12 | NPS Pharmaceuticals, Inc. | Treatment of short bowel syndrome patients with colon-in-continuity |
| US20090175795A1 (en) | 2005-07-29 | 2009-07-09 | Amprotein Corporation | Chimeric therapeutic agents |
| WO2007067828A2 (en) * | 2005-10-24 | 2007-06-14 | Centocor, Inc. | Glp-2 mimetibodies, polypeptides, compositions, methods and uses |
| JP5290177B2 (ja) * | 2006-08-31 | 2013-09-18 | セントカー・インコーポレーテツド | Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途 |
| JP2008247789A (ja) * | 2007-03-30 | 2008-10-16 | Kissei Pharmaceut Co Ltd | クローン病に伴う腸管狭窄の進展抑制用医薬組成物 |
| PT2755675T (pt) | 2011-09-12 | 2018-10-11 | Amunix Operating Inc | Composições de péptido semelhante a glucagão-2 e métodos para produzir e utilizar as mesmas |
| US9458214B2 (en) * | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| KR101895047B1 (ko) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
| CN104540850B (zh) | 2012-05-03 | 2018-05-18 | 西兰制药公司 | 胰高血糖素样肽2(glp-2)类似物 |
| CN106029087A (zh) * | 2013-12-20 | 2016-10-12 | 印第安纳大学研究及科技有限公司 | 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽 |
| KR101825048B1 (ko) * | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
-
2018
- 2018-11-05 KR KR1020207013387A patent/KR102825098B1/ko active Active
- 2018-11-05 EP EP18872377.9A patent/EP3706774A4/en active Pending
- 2018-11-05 MX MX2020004620A patent/MX2020004620A/es unknown
- 2018-11-05 CN CN201880071791.3A patent/CN111629745A/zh active Pending
- 2018-11-05 JP JP2020526107A patent/JP7296958B2/ja active Active
- 2018-11-05 AU AU2018360744A patent/AU2018360744A1/en not_active Abandoned
- 2018-11-05 WO PCT/US2018/059175 patent/WO2019090209A1/en not_active Ceased
- 2018-11-05 BR BR112020008936-2A patent/BR112020008936A2/pt unknown
- 2018-11-05 CA CA3079523A patent/CA3079523A1/en active Pending
- 2018-11-05 US US16/761,606 patent/US11660328B2/en active Active
- 2018-11-05 IL IL274098A patent/IL274098B2/en unknown
- 2018-11-06 TW TW107139266A patent/TW201922279A/zh unknown
- 2018-11-06 AR ARP180103232A patent/AR113835A1/es unknown
-
2020
- 2020-05-04 ZA ZA2020/02080A patent/ZA202002080B/en unknown
-
2023
- 2023-06-13 JP JP2023096692A patent/JP7752152B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111629745A (zh) | 2020-09-04 |
| WO2019090209A1 (en) | 2019-05-09 |
| MX2020004620A (es) | 2020-10-12 |
| EP3706774A1 (en) | 2020-09-16 |
| CA3079523A1 (en) | 2019-05-09 |
| KR102825098B1 (ko) | 2025-06-26 |
| AU2018360744A1 (en) | 2020-05-07 |
| KR20200085763A (ko) | 2020-07-15 |
| RU2020118172A (ru) | 2021-12-08 |
| US20210169986A1 (en) | 2021-06-10 |
| TW201922279A (zh) | 2019-06-16 |
| IL274098B2 (en) | 2024-12-01 |
| JP2023107883A (ja) | 2023-08-03 |
| JP7752152B2 (ja) | 2025-10-09 |
| IL274098B1 (en) | 2024-08-01 |
| ZA202002080B (en) | 2025-11-26 |
| US11660328B2 (en) | 2023-05-30 |
| JP7296958B2 (ja) | 2023-06-23 |
| BR112020008936A2 (pt) | 2020-10-20 |
| EP3706774A4 (en) | 2021-09-08 |
| JP2021502389A (ja) | 2021-01-28 |
| IL274098A (en) | 2020-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113835A1 (es) | Análogos y pepticuerpos de glp-2 para la administración antes, durante o después de la cirugía | |
| AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| MX2016015466A (es) | Metodo para tratar dializado, sistema de dialisis y metodo para pre-evaluar pacientes de dialisis para el tratamiento con los mismos. | |
| JP2016519078A5 (enExample) | ||
| BR112015021446A2 (pt) | métodos cirúrgicos empregando composições de peptídeo amfifílico purificado | |
| BR112016010383A2 (pt) | compostos de pyy seletivos e usos dos mesmos | |
| AR103246A1 (es) | Derivados de fgf21 y sus usos | |
| ECSP12011803A (es) | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas | |
| AR045906A1 (es) | Composicion farmaceutica para mejorar la solubilidad de farmacos hidrofobicos | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| CL2020001688A1 (es) | Vacunas liquidas de virus vivos envueltos. | |
| EA201591701A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| EP3773530A4 (en) | RAPID IMPROVEMENT OF VASCULAR DISEASES BY ADMINISTRATION OF VITAMIN K | |
| MX2018012941A (es) | Formulaciones y metodos para tratar organismos fotosinteticos y mejorar las calidades y cantidades de los rendimientos con formulaciones de compuestos de glicano. | |
| MX2023000398A (es) | Analogos de insulina novedosos y usos de estos. | |
| CO2018000768A2 (es) | Administración intravenosa de citrulina durante la cirugía | |
| CL2019000624A1 (es) | Formulaciones de buprenorfina de liberación sostenida. | |
| EA201591910A1 (ru) | Стабильный раствор бромфенака | |
| EA201792170A1 (ru) | Производные индола | |
| EA201992436A1 (ru) | Композиции с улучшенной стабильностью и биодоступностью для введения (e)-2,6-диалкокси 4-замещенных бензилсульфонов | |
| RU2013126506A (ru) | Способ лечения перелома межмыщелкового возвышения большеберцовой кости | |
| MX383214B (es) | COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACIÓN DE TRAUMA DE TEJIDO BLANDO. | |
| PE20191462A1 (es) | Composicion liquida que contiene pradofloxacina |